Form 13-F position report

CARDIOL THERAPEUTICS INC

Reported by Kovack Advisors Inc

Company profile Manager portfolio Source filing
CRDL CUSIP 14161Y200 Manager CIK 0001728321
Latest reported change

Reported 30,000 shares, unchanged from the prior quarter.

Reported value -25.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2026
Shares 30,000 Quarter-end amount reported
Reported value $31,500 Fair value at quarter end
Consecutive quarters held 2 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

2 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Unchanged 30,000 0 (0.0%) < 0.01% $31,500 2026-07-29
Q1 2026 New 30,000 +30,000 (0.0%) < 0.01% $42,000 2026-05-13
Institutional context

Who else reported the position

58 managers reported CARDIOL THERAPEUTICS INC for Q2 2026.

Manager Activity Shares Change % of reported 13F Reported value Tenure
MMCAP International Inc SPC Added 15,598,560 +246,243 1.4% $16,534,474 19 qtrs
Tejara Capital Ltd Reduced 5,113,822 -16,300 2.23% $5,420,651 15 qtrs
Ikarian Capital LLC Added 3,325,000 +600,000 0.38% $3,524,500 2 qtrs
BOOTHBAY FUND MANAGEMENT LLC Added 975,721 +180,840 0.01% $1,034,264 2 qtrs
CITADEL ADVISORS LLC Reduced 796,529 -23,375 < 0.01% $844,320 4 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 772,837 +543,031 < 0.01% $819,207 2 qtrs
TWO SIGMA INVESTMENTS LP Added 746,937 +212,726 < 0.01% $791,753 4 qtrs
INTEGRITY ALLIANCE LLC Reduced 388,492 -76,533 0.01% $411,802 3 qtrs
MORGAN STANLEY Added 355,030 +104,609 < 0.01% $376,332 9 qtrs
The Goldman Sachs Group Inc Added 333,900 +1,500 < 0.01% $353,934 15 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
July 29, 2026
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
0
Shared
0
None
30,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.